Myeloma Novel Drug Discovery Ver 1.2
ConditionMultiple Myeloma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorInstitute of Cancer Research, United Kingdom
About this trial
Myeloma is a bone marrow cancer with over 5000 patients diagnosed in the UK each year. Researchers are committed to improving understanding of myeloma and developing more effective treatments with fewer side effects in order to improve patient outcomes. In order to do this, researchers are collecting samples of blood and bone marrow to test the activity of potential new treatments in the laboratory and to understand what may be the cause of some treatments not working.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Participants who have a diagnosis, or suspected diagnosis, of myeloma or related plasma cell disorder
Participants who are undergoing a peripheral blood or bone marrow aspirate sampling for diagnostic, staging or follow-up purposes, before, whilst or after receiving anti-myeloma treatment
Participants aged 18 years of age or above
Participants willing to consent to an additional sample being taken at the time of their peripheral blood or bone marrow aspirate sampling
Disqualifiers
Participants unable to provide consent
Participants with known active infectious diseases (e.g. HIV, Hepatitis B/C, COVID) that pose a risk to the use of the sample in the laboratory
Trial population
Participants who have a diagnosis, or suspected diagnosis, of myeloma or related plasma cell disorder
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Observational study - sample collection only.
Other interventionNo intervention - blood and/or bone marrow sample collection only
Treatment groups
250 Participants
are divided into 1 treatment groupGroup A: Participants with a diagnosis, or suspected diagnosis, of myeloma or related plasma cell disorder1 intervention
Trial outcomes
Primary outcomes
1
Cell viability
Myeloma cell viability when incubated with standard of care and novel compounds.
Time frame
12 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Institute of Cancer Research, United Kingdom
Lead sponsor
Royal Marsden NHS Foundation Trust
Collaborator
Source ClinicalTrials.gov